个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Du Manling[1] * ; Ouyang Yong[2] * ; Meng Fansu[3] * ; Zhang Xingwang[1] ; Ma Qianqian[1] ; Zhuang Yong[1] ; Liu Hui[1] ; Pang Mujuan[1] ; Cai Tiange[4,*1] ; Cai Yu[1,5,*2] ;
机构： [1]College of Pharmacy, Jinan University, Guangzhou 510632, China [2]Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou 510800, China [3]Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of TCM, Zhongshan, Guangdong 528400, China [4]College of Life Sciences, Liaoning University, Shenyang 110036, China [5]Cancer Research Institute of Jinan University, Guangzhou 510632, China
出处：
DOI： 10.1016/j.ijpharm.2019.03.006
ISSN：

关键词： Polymer-lipid hybrid nanoparticles Psoralen Breast cancer MCF-7 cells

摘要：
A polymer-lipid hybrid nanocarrier was developed to encapsulate psoralen (PSO) to improve its water solubility and bioavailability. The effects of PSO-loaded polymer-lipid hybrid nanoparticles (PSO-PLNs) on breast cancer MCF-7 cells were investigated. PSO-PLNs were prepared through a nanoprecipitation method and were optimized by a central composite design-response surface methodology using particle size and entrapment efficiency as indices. Dynamic light scattering and transmission electron microscopy analysis confirmed the physicochemical characterizations of PSO-PLNs, which had an average size of 93.44 ± 2.39 nm and a zeta potential of -27.63 ± 0.31 mV. In vitro drug release of PSO-PLNs was evaluated using dialysis and showed a delayed release compared with free PSO. The in vivo anticancer efficiency of PSO-PLNs was appreciated using a MCF-7 breast tumor model. Administration of PSO-PLNs showed similar antitumor efficacy but lower toxicity compared with doxorubicin. Our designed nanocarriers successfully optimized the pharmacokinetics of PSO via improved systemic delivery. Copyright © 2019. Published by Elsevier B.V.

基金：
National Natural Science Foundation of China (81173215, 81273707); the Natural Science Foundation of Guangdong (2016A030311037); the Science and Technology Program of Guangzhou (2014J4500005, 201704030141); the Science Program of the Department of Education of Guangdong (2015KGJHZ012); the Science and Technology Program of Guangdong (2015A050502027); and the Special Project of International Scientific and Technological Cooperation in Guangzhou Development District (2017GH16).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 药学
第一作者：
第一作者机构： [1]College of Pharmacy, Jinan University, Guangzhou 510632, China
共同第一作者：
通讯作者：
通讯机构： [1]College of Pharmacy, Jinan University, Guangzhou 510632, China [4]College of Life Sciences, Liaoning University, Shenyang 110036, China [5]Cancer Research Institute of Jinan University, Guangzhou 510632, China [*1]College of Life Sciences, Liaoning University, Shenyang 110036, China [*2]College of Pharmacy, Jinan University, Guangzhou 510632, China,Cancer Research Institute of Jinan University, Guangzhou 510632, China
推荐引用方式(GB/T 7714)：
Du Manling,Ouyang Yong,Meng Fansu,et al.Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer.[J].International journal of pharmaceutics.2019,561:274-282.doi:10.1016/j.ijpharm.2019.03.006.
APA：
Du Manling,Ouyang Yong,Meng Fansu,Zhang Xingwang,Ma Qianqian...&Cai Yu.(2019).Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer..International journal of pharmaceutics,561,
MLA：
Du Manling,et al."Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer.".International journal of pharmaceutics 561.(2019):274-282

相关文献

[1]iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability [2]Exploring the potential of functional polymer-lipid hybrid nanoparticles for enhanced oral delivery of paclitaxel [3]Corrigendum: Furanodiene Induces Extrinsic and Intrinsic Apoptosis in Doxorubicin-Resistant MCF-7 Breast Cancer Cells via NF-κB-Independent Mechanism. [4]大黄素阻抑人乳腺癌MCF-7细胞增殖和细胞周期进程 [5]Furanodiene Induces Extrinsic and Intrinsic Apoptosis in Doxorubicin-Resistant MCF-7 Breast Cancer Cells via NF-κB-Independent Mechanism. [6]Baicalin-loaded folic acid-modified albumin nanoparticles (FA-BSANPs/BA) induce autophagy in MCF-7 cells via ROS-mediated p38 MAPK and Akt/mTOR pathway [7]Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. [8]The estrogenic properties of Danggui Buxue Tang, a Chinese herbal decoction, are triggered predominantly by calycosin in MCF-7 cells. [9]补骨脂素对乳腺癌MCF-7细胞的体外抗肿瘤作用 [10]Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation.

资源点击量：2022 今日访问量：0 总访问量：648 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号